Abstract Recently developed multi-targeted ligands are novel drug candidates able to interact with monoamine oxidase A and B; acetylcholinesterase and butyrylcholinesterase; or with histamine N-methyltransferase and histamine H 3 -receptor (H 3 R). These proteins are drug targets in the treatment of depression, Alzheimer's disease, obsessive disorders, and Parkinson's disease. A probabilistic method, the Parzen-Rosenblatt window approach, was used to build a ''predictor'' model using data collected from the ChEMBL database. The model can be used to predict both the primary pharmaceutical target and off-targets of a compound based on its structure. Molecular structures were represented based on the circular fingerprint methodology. The same approach was used to build a ''predictor'' model from the DrugBank dataset to determine the main pharmacological groups of the compound. The study of offtarget interactions is now recognised as crucial to the understanding of both drug action and toxicology. Primary pharmaceutical targets and off-targets for the novel multitarget ligands were examined by use of the developed cheminformatic method. Several multi-target ligands were selected for further study, as compounds with possible additional beneficial pharmacological activities. The cheminformatic targets identifications were in agreement with four 3D-QSAR (H 3 R/D 1 R/D 2 R/5-HT 2a R) models and by in vitro assays for serotonin 5-HT 1a and 5-HT 2a receptor binding of the most promising ligand (71/MBA-VEG8).
Introduction
The diverse cerebral mechanisms implicated in neurodegenerative disorders [1] and neurological diseases [2] [3] [4] [5] [6] and the heterogeneous but overlapping nature of phenotypes indicated that multitarget strategies may be appropriate for the improved treatment of complex brain diseases. It is now accepted that drug action can involve plural targets and that polypharmacology-interacting with multiple targets to address disease in more subtle and effective ways-will be a key pharmacological concept in future. MTDL approach [7] [8] [9] [10] has been applied for development of CNS drugs with improved efficacy compared to their precursors, such as dopamine D 2 /D 3 /5-HT 2A antagonism plus 5-HT 1A partial agonism or dual PDE-4/GSK-3 inhibitors for therapy of schizophrenia [11] [12] [13] , monoamine reuptake inhibition plus 5-HT 2C antagonist properties for tricyclic antidepressants [14] [15] [16] , multi-target AChE/BuChE/MAO-A/MAO-B inhibitors for therapy of neurodegenerative Alzheimer's (AD) and Parkinson's diseases (PD) [7, 17, 18] , and range of CNS drug candidates with additional activity on various targets [19] [20] [21] [22] . The potential clinical advantages of novel classes of multi-target agents are efficacy and speed of action, improved tolerance, and therapeutic range [8] [9] [10] 14] . Therefore, development of multi-targeted compounds, with selective ranges of cross-reactivity, as novel drug candidates against neurological diseases was one of the main aims of ourrecent studies [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
Understanding how the neurotransmitter systems interact is also important in optimizing therapeutic strategies. Pharmacological intervention on one will often influence another, such as the well-established serotonin-dopamine interaction [38, 39] or the dopamine-glutamate interaction [40, 41] . This is a second reason to design compounds with specific, known cross-reactivity. An example of a drug with activity on different neurotransmitter systems is the cognitive enhancer, memantine, that binds as an uncompetitive antagonist at glutamatergic NMDA receptors [42] inhibiting the influx of Ca 2? ions that would result in neuronal excitotoxicity. Memantine also acts as a non-competitive antagonist at the 5-HT 3 receptor and binds to dopamine D 2 receptors and nAChRs [43] .
Many compounds already in databases have been investigated for multiple targets as part of drug-discovery programs. Mining this information can provide experimental information useful for building pharmacophores. Data for three groups of new dual or multi-target compounds were also used in this process and to develop 3D-QSAR models for activity evaluation at the selected targets. The first group contains novel carbonitrile-aminoheterocyclic inhibitors of both MAO A and B enzymes [23] . More selective MAO A inhibition was observed for dicarbonitrile aminofuran derivatives of the dataset [23] .
The second group includes acetylene/indol/piperidines [24] [25] [26] [27] and pyridine derivatives [28, 29] , as compounds with appreciable inhibitory profile for MAO, AChE, and BuChE. These agents are potentially effective multitargeted ligands in therapy for Alzheimer's disease [44, 45] .
The third group contains the recently synthesised multipotent histamine H 3 R antagonists that simultaneously possess strong inhibitory potency on catabolic HMT enzyme [30, 31] . These compounds are dual acting procognitive agents with possible beneficial effects in many psychiatric and neurodegenerative diseases [36, 37] .
We have previously demonstrated that prohibited substances can be classified into athletic performanceenhancing classes using MACCS, CDK, and UFS-MACCS hybrid cheminformatics descriptors and machine learning methods including Random Forest, k-nearest neighbours and Naive Bayes [46] [47] [48] . In silico prediction of protein targets is a new research area useful for understanding molecular bioactivities, performance-enhancing effects of molecules, target predictions in early drug development and toxicology [49] [50] [51] [52] [53] [54] [55] [56] , allowing the determination of both the primary pharmaceutical target and the off-targets from the structure of a compound. In silico ligand-target prediction helps us both to infer and to understand molecular bioactivities of test compounds. As well as being valuable for understanding the primary pharmaceutical roles of molecules, prediction of ligand-target associations facilitates both in silico polypharmacology and toxicology. Our interest is in predicting ligand-target associations that will allow us to define binding profile of ligand and in suggesting theoretical and experimental approaches directed towards gaining a deeper understanding of possible pharmacological effects. Our novel methodology, based on circular fingerprint (CFP) descriptors of compounds [57] and information data mined in the ChEMBL database, was very successfully applied in prediction of unexplored compound-to-target associations using a set of the WADA prohibited compounds [58] . A similar approach [58] was now applied to determine primary pharmaceutical targets and off-targets for our novel multi-target ligands (1-134) [23] [24] [25] [26] [27] [28] [29] [30] [31] as a crucial step in understanding the pharmacological and toxicological profiles of these novel compounds. Incorporation of target predictions into our drug design workflow represents one of the main advances of this study.
The publicly available ChEMBL database [59] contains bioactivity data for hundreds of thousands of different molecules on thousands of protein targets. When this information is combined with data from sources such as DrugBank [60] , results can also be associated with specific biological and pharmacological activities. One of the first steps of our methodology is to apply a clustering algorithm capable of identifying structurally different groups of ligands and finding the optimum number of clusters for a given database. Those molecules, which have been examined in different assays, may have activities for more then one target. The target prediction methods presented here can predict unexplored compound-to-target associations and patterns of activity against the whole set of targets to be assessed. Our approach allows identification of novel compounds associated with a given pharmacological function.
These predictions can help to early identify any potential beneficial pharmacological effects, or unwanted side effects, of the novel multi-target agents [23] [24] [25] [26] [27] [28] [29] [30] [31] examined in this study. The compounds with better pharmacological activity profiles can be further examined by 3D-QSAR for their interaction with the targets, and then selected for experimental testing. Application of these cheminformatic and 3D-QSAR methods in early stage of drug discovery could significantly reduce the need for animal or human experiments. Our results can be interpreted as a quantitative assessment of protein target interactions that will prevent unpromising novel compounds being examined in vitro and in vivo.
Methods

Filtered and refined families of the ChEMBL dataset
The ChEMBL database presently has 8,845 targets and 1,059,559 unique compounds, which are connected with the targets, based on experimental activity data derived from 44,682 publications. Each of the targets has compounds associated with it. Each such association comes from the experimental data indicating activity of the molecule against the target. However, some molecules are found to be inactive. A compound in ChEMBL database can be associated with more then one target family. In order to predict whether a given molecule will be active against a particular target, we first applied a number of rules on the ChEMBL dataset in order to generate sets of molecules that are experimentally determined to be bioactive [IC 50 
. These rules depend on the ranges of values against that target and the distribution of values of the relevant quantity within ChEMBL [56, 58] . This process generates bioactivity based filtered families. Our recently developed PFClust clustering [61] was applied to all the filtered ChEMBL families, which subdivided each family into smaller groups based both on ligand structure and their proven activity on a given protein target [56, 58] . The compounds were clustered on the basis of their chemical structures, described by circular fingerprints (CFPs) [57] . This leads to a set of refined families, each consisting of a group of molecules, which share similar chemical structure and bioactivity. The refined families of the ChEMBL dataset will allow us to identify the different sets of ligands [56, 58, 61] .
Molecular fingerprints and similarities
The studied molecules are represented as CFP vectors [57] . Pairwise similarity between two molecules is calculated by Tanimoto similarity scores [62] . The obtained Tanimoto similarity scores are then transformed into probabilities (pairwise p values) using an appropriate kernel function. The Gaussian distribution was proven to be the best suited kernel function for the refined ChEMBL dataset [58] . In order to predict molecule-target pairs, we had to calculate how similar a given molecule x i is to the members of family x = {x 1 , x 2 , …, x n } using the refined ChEMBL dataset. We first calculated the distribution of p(t[x i , x]) between molecule x i and the known members of x. The probability density function of p(t[x i , x]) is then estimated by use of the Parzen-Rosenblatt (PR) [63, 64] kernel density estimation method.
Methodology validation
Our methodology is further validated by use of a fivefold Monte Carlo cross-validation for: the original ChEMBL dataset with all the compounds assigned to their label based ChEMBL families; the bioactivity based filtered ChEMBL families; and finally the refined ChEMBL families obtained by PFClust clustering of the filtered dataset. In each cross-validation, we remove 10 % of the members of each family, which are then used as a test set of queries. To investigate the relative performances using the three different definitions of families, we calculated two validation metrics. To investigate the relative performance of each methodology, we classified as a true positive (TP) a hit to the parent family from which the query compound was taken, and as false positives (FP) hits to all other families. The TPs and FPs obtained in the first four top hits for each query in all the crossvalidation runs for each of the three definitions of families were used to calculate the Matthews correlation coefficient (MCC) [65] , as a measure of prediction success. The results of the fivefold Monte Carlo cross-validation proved that the best performing model was the one based on the refined families [58] .
Identifying the off-targets of the novel multipotent compounds
We used 134 novel drug candidates (1-134) ( Fig. 1 ) able to interact with MAO A and B; AChE and BuChE; or with HMT and histamine H 3 -receptor (Table 1) , as queries against the refined ChEMBL dataset [58] .
For the three classes of compounds ( Fig. 1 : 1-134) we used our cheminformatic workflow ( Fig. 2) to retrieve from the refined ChEMBL dataset the most significant families having p values \0.10 (PR-score B0.10). This allows us to identify relevant biological targets for each group of studied compounds. To validate the methodology, we first checked whether these molecules have experimentally determined activities against these targets in ChEMBL. We created a matrix in which the rows were the examined compounds, the columns were the relevant families retrieved from ChEMBL, and the values were the relevant values of the Parzen-Rosenblatt function f(x i , x). Each row of this matrix was considered as a vector and we calculated the pairwise Euclidean distances between the points. The calculated distances were further used to allow PFClust to cluster the examined compounds. For each class of ligands, we performed a ChEMBL database search and a vector of PR-scores against the refined families was retrieved. Using these position vectors for each compound, we calculated the Euclidean distances between the resulting points and a similarity matrix was created. Finally, we clustered the vectors using PFClust [61] .
3D-QSAR modeling
Based on the ranges and distribution of obtained PR-scores for the MAO/ChE inhibitors against the refined ChEMBL 
5-HT 1A binding assay
Radioligand binding assays were performed following a published procedure [75] . Cerebral cortex from male Sprague-Dawley rats (180-220 g) was homogenized in 20 volumes of ice-cold Tris-HCl buffer (50 mM, pH 7.7) with a Polytron PT10, Brinkmann Instruments (setting 5 for 15 s), and the homogenate was centrifuged at 50,000g for 10 min. The resulting pellet was then resuspended in the same buffer, incubated for 10 min at 37°C, and centrifuged at 50,000g for 10 min. The final pellet was resuspended in 80 volumes of the Tris-HCl buffer containing 10 lM pargyline, 4 mM CaCl 2 , and 0.1 % ascorbate. To each assay tube was added the following: 0.1 mL of the drug dilution (0.1 mL of distilled water if no competing drug was added), 0.1 mL of In the 5-HT 2C assays, mianserin (1.0 lM) was used to define nonspecific binding, and 100 nM spiperone was added to all tubes to block binding to 5-HT 2A receptors. Tubes were incubated for 15 min at 37°C, filtered on Schliecher and Schuell (Keene, NH, USA) glass fibre filters presoaked in polyethylene imine, and washed with 10 mL of ice-cold buffer. Filters were counted at an efficiency of 50 %.
Results
Identifying the targets of the query molecules
The TPs and FPs obtained in the first four top-ranked positions for each query compound in all the cross-validation runs for each of the three definitions of families confirmed previous observations that the refined families gave a significantly better predictivity (MCC: 0.66) [58] . Thus, for each of the four classes of compounds ( Fig. 1: 1-134) , we examined the refined ChEMBL families using every such compound as a query. Relative performance of the cheminformatic methodology was further tested with true positives (TPs) and false positives (FPs) ligands, selected from the examined data set. Selective and potent ligands were used as TPs in the study: tacrine/donepezil (AChE/BuChE), FA-73 (MAO-B), clorgiline (MAO-A), and 18-Hetero (HMT/H 3 -R). As FPs were used compounds with no activity on the specific target such as: clorgiline (AChE/BuChE), tacrine/donepezil (MAO-B), tacrine/donepezil (MAO-A), and clorgiline (HMT/H 3 -R). For all compounds, we calculated heat map with the top predictions (PR-score B0.10) that summarizes the experimental validation for the most confident predictions (PR-scores B0.10). The selected TPs and FPs confirmed very high predictive potential of the developed method. The top targets predictions for all examined compounds ( Fig. 1: 1-134 ) by applying the cheminformatic methodology against the refined families ChEMBL are shown in Fig. 4 Figure 1 ) are then compared with ChEMBL results with the goal of associating specific biological/ pharmacological activities with ligand-target interactions.
MAO inhibitors
For the first group of novel carbonitrile-aminoheterocyclic MAO inhibitors (Fig. 1: 1-17 ) [23] were not predicted to interact with MAO within the top predictions (PR-score B0.10) by querying the 17 ligands against the refined ChEMBL families (Fig. 4; Supplementary Table 1 ). Since the structures and activities of the novel class of MAO inhibitors ( Fig. 1: 1-17) [23] have just recently been published and still are not included in the ChEMBL dataset our cheminformatic method couldn't find significant similarity between the query compounds ( Fig. 1: 1-17 ) and the refined ChEMBL dataset.
For the carbonitrile-oxazole derivatives ( Fig. 1: 1/CND1a, 2/CN-D1b, 3/CN-D1c 4/CN-D1d, 5/CN-D1e, 6/CND1f, 7/CN-D2b) [23] affinity was predicted with a good PR-score (PR-score B0.10) for caspase-1 and caspase-7 families. These MAO inhibitors were also classified as folic acid antagonists, antimetabolites-antineoplastics or protein kinase inhibitors by applying the cheminformatic methodology against the DrugBank dataset (Supplementary Figure 1 ; Supplementary Table 2 ). The targets retrieved from the ChEMBL data base (caspase families) were in accordance with the DrugBank results.
MAO/ChE inhibitors
The MAO/ChE inhibitors are clustered by structure into three subgroups: acetylene/indol derivatives as potent inhibitors of MAO A and MAO B (Fig. 1: 44-55 ) [27] , the acetylene/indol/piperidines as MAO A, MAO B, AChE, and BuChE inhibitors ( Fig. 1: 18-43, 56-77, 79-85 ) [24] [25] [26] , while the pyridine derivatives are AChE and BuChE inhibitors ( Fig. 1: 78, 86-100) [28, 29] .
The top targets predictions for examined MAO/ChE inhibitors ( Fig. 1: 44-100 ) by applying the cheminformatic methodology against the refined ChEMBL dataset are shown in Fig. 4 and Supplementary Table 1 .
The compounds in the subgroup of acetylene/indol derivatives ( Fig. 1: 44-55 ) [27] are identified as MAO inhibitors; the acetylene/indol/piperidines ( Fig. 1: 18-43 , 56-77, 79-85) [24] [25] [26] are identified as MAO/ChE inhibitors; and the subgroup of pyridine derivatives ( Fig. 1: 78 , 86-100) [28, 29] as ChE inhibitors within the top predictions (PR-score B0.10) ( Table 2) . TP control were tacrine/ donepezil (AChE/BuChE), FA-73 (MAO-B), and clorgiline (MAO-A), while clorgiline (AChE/BuChE), tacrine/donepezil (MAO-B), and tacrine/donepezil (MAO-A) were used as FPs. Good agreement obtained between the theoretical and the experimental results represents experimental confirmation of reliability and accuracy of the applied cheminformatic methodology.
Compounds 31/PF96-Donz-D8, 33/PF96-Donz-D10, 34/PF96-Donz-11, 36/PF96-Donz-D13, 60/Donz-D6, 62/Donz-D8, 63/Donz-D9, and 68/MBA-71, are identified as ligands for the histamine H 3 receptor by applying the cheminformatic methodology against the refined ChEMBL dataset (Table 3) .
Compounds 62/Donz-D8, 63/Donz-D9, 67/MBA-50, 70/MBA-73, and 71/MBA-VEG8 are determined as ligands for dopamine D 1 receptors by applying the cheminformatic methodology against the refined ChEMBL dataset ( Fig. 5; Table 3 ).
Compound 63/Donz-D9 is identified as a ligand for dopamine D 2 receptors by applying the cheminformatic methodology against the refined ChEMBL dataset ( Fig. 5 ; Table 3 (Fig. 5) . The top ranked targets of the ligands obtained by the cheminformatic method were in good accordance with the corresponding activities of ligands predicted by the 3D-QSAR (H 3 R/D 1 R/D 2 R/5-HT 2a R) models ( Fig. 6; Table 3 ). These predictions are testable by future experiments.
The in vitro 5-HT 1a R and 5-HT 2a R binding assay for 71/ MBA-VEG8 determined the Ki for 5-HT 1a R as 108 nM and the Ki for 5-HT 2a R as 14.2 nM (Fig. 7) .
These results experimentally confirmed high prediction capacity of the applied cheminformatic methodology. The in vitro binding assay of 71/MBA-VEG8 on 5-HT 2c R determined no affinity. This result can be explained by the higher PR-score for 71/MBA-VEG8 on 5-HT 2c R, then on 5-HT 1a R and 5-HT 2a R. The third group (101/1-Hetero-134/34-Hetero) contains multipotent histamine H 3 receptor (H 3 R) antagonists with inhibiting activity on HMT enzyme [30, 31] . For several ligands of the third group, 109/9-Hetero, 128/28-Hetero, 131/31-Hetero, 133/33-Hetero, 134/34-Hetero, is experimentally determined inhibiting activity on AChE/BuChE enzymes too [31] .
The top targets predictions for examined H 3 R/HMT/ ChE ligands ( Fig. 1: 101/1-Hetero-134/34-Hetero) by applying the cheminformatic methodology against the refined ChEMBL dataset are shown in Fig. 4 and Supplementary Table 1 .
The piperidine/quinoline derivatives ( Fig. 1: 101/1-Hetero-134/34-Hetero) [30, 31] are defined as H 3 R/HMT ligands within the top predictions (PR-score B0.10) ( Table 4 ). The 109/9-Hetero, 131/31-Hetero, and 133/33-Hetero compounds are also identified as AChE/BuChE inhibitors by applying the cheminformatic methodology against the refined ChEMBL dataset (Table 4) .
For all top ranked targets (PR-scores B0.10) of the H 3 R/ HMT/ChE ligands are experimentally confirmed strong ligand-target affinities ( Table 4 ). The accordance between the predicted pharmacological targets and the in vitro activities of the H 3 R/HMT/ChE ligands (Table 4) has proved high accuracy and reliability of the applied cheminformatic methodology against the refined ChEMBL dataset.
Based on the identified off targets (Table 5 ) the compounds 102/2-Hetero, 131/31-Hetero, 132/32-Hetero, and 133/33-Hetero are selected for further experimental study as promising novel agents with possible beneficial effects in treatment of depression, Alzheimer's disease, and obsessive disorders. Figure 1; Supplementary Table 2. ). The targets retrieved from the ChEMBL data base (H 1 , H 3 , NMDA, and D 2 receptors) accorded well with the DrugBank results.
Discussion
Our current methodology has confirmed to enhance the predictive power of the CFP representations, and that the filtering and refinement of ChEMBL families enriches our results. The refined ChEMBL dataset and our protein target prediction approach could serve as a baseline for further methodologies. The developed workflow represents a truly portable methodology that can easily be used in initial phase of drug design process.
Having thus fivefold cross-validated cheminformatic approach, we used it to identify the protein targets associated with the 134 multipotent compounds against neurological diseases able to interact with MAO A and B; AChE and BuChE; or with HMT and histamine H 3 -receptor. Across the three classes considered, we find a combination of expected and unexpected protein targets for the examined ligands. Good agreement between the predicted pharmacological targets and the experimental results for the MAO/ChE and H 3 R/HMT/ChE ligands (Tables 2,  4 ) has proved high reliability and accuracy of the applied cheminformatic methodology. (Fig. 8) .
Serotonin (5-HT) plays a major role in the pathophysiology and treatment of depression, anxiety, schizophrenia, and various forms of dementia including Alzheimer's disease [77] . Therefore, serotonin 5-HT 1a partial agonists/ antagonists and 5-HT 2a antagonists have shown effectiveness in improving cognition in depression [8, 14, 16, 77] , schizophrenia [15, [78] [79] [80] ], Alzheimer's and Parkinson's diseases [81] [82] [83] [84] .
Based on results of previous studies [78, 85] it was proposed that drugs with potent serotonin 5-HT 1a or 5-HT 2a antagonistic actions may improve cognition in various neurodegenerative disorders due to a association with NMDA receptors [83, 86] .
Few recent studies of memantine, as a non-competitive antagonist of glutamatergic NMDA receptors [87, 88] , demonstrated that this drug for treatment of AD also competitively inhibits both MAO-A and MAO-B in nanomolar range and inhibits the reuptakes of both DA and 5-HT. The memantine induce 5-HT 2a receptor-mediated head-twitch response (HTR) and head-weaving side effects [89, 90] . These abnormal behaviours developed during memantine therapy of AD were inhibited by co-administration of haloperidol (D 1 /D 2 /5-HT 2a antagonist) or ketanserine (5-HT 2a antagonist) [87] .
Based on all these findings is assumed that multi-potent ligands targeting AChE/MAO-A/MAO-B and also D 1 /D 2 / 5-HT 2a /H 3 , such as 63/Donz-D9 and 71/MBA-VEG8, are promising novel drug candidates with improved efficacy and safety in treatment of Alzheimer's and related diseases.
Also, numerous pharmacological, preclinical and clinical studies proved that histamine H 3 R antagonists/inverse agonists facilitate the corticolimbic liberation of acetylcholine, noradrenaline, dopamine, glutamate, and serotonin [2, 3, 5] and therefore demonstrate efficacy in diverse preclinical models of cognitive deficits [91] . 
Experimental
The computations described in ''Methods'' section were carried out on a custom-built computer using an Intel i3 processor @ 3.10 GHz with 4 GB of RAM.
